CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 6 target
Drug / intervention
JWK008 Single intravenous infusion administrationgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06519552
NCT06519552Phase 1RecruitingOn TrackUpdated 23mo ago

A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 Given by a Single Intravenous Infusion in Patients With Mucopolysaccharidosis Type I

West China Hospital·interventional·Posted Jul 25, 2024·Updated Jul 25, 2024

In Brief

A Phase 1 clinical trial evaluating JWK008 Single intravenous infusion administration for Mucopolysaccharidosis Type I. Currently recruiting, targeting 6 participants across 1 site.

Detailed Summary

This study is a single-center, single-arm, non-randomized, open-label, non controlled, dose-escalation, prospective clinical trial designed to assess the safety, tolerability, and preliminary efficacy of JWK008 injection in patients with MPS I.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20252026202720282029
First PostedJul 25, 2024
Enrollment StartJul 22, 2024
Primary CompletionJun 22, 2026
Study CompletionJun 22, 2029
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.9 years ago

Interventions

JWK008 Single intravenous infusion administrationgenetic

Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a "3+3" dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant.